LABT.US Lakewood-Amedex Biotherapeutics Inc. Common Stock

Healthcare Biotechnology USA Stocks
0.2824 USD
Close of Nov 15, 2026
0.1700 9.82
Market cap
USD 669K
P/E
-
P/B
0.15x
ROE
-216.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is LABT.US undervalued?

Graham number

The Graham number of Lakewood-Amedex Biotherapeutics Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Lakewood-Amedex Biotherapeutics Inc. Common Stock fundamental analysis

No fundamental analysis for Lakewood-Amedex Biotherapeutics Inc. Common Stock yet.

Lakewood-Amedex Biotherapeutics Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Lakewood-Amedex Biotherapeutics Inc. Common Stock

Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known …

Full company profile